NCT04453202View on ClinicalTrials.gov

A Study to Evaluate a Range of Dose Levels of an Adenovirus Serotype 26 (Ad26.RSV.preF)-Based Vaccine in Older Adults

PHASE2CompletedINTERVENTIONAL
Enrollment

459

Participants

Timeline

Start Date

July 16, 2020

Primary Completion Date

September 24, 2020

Study Completion Date

April 9, 2021

Conditions
Healthy
Interventions
BIOLOGICAL

RSV Vaccine

Participants will receive a single IM injection of an Ad26-based RSV vaccine on Day 1.

OTHER

Placebo

Participants will receive a single IM injection of placebo on Day 1.

Trial Locations (9)

20850

Optimal Research, Rockville

33134

Clinical Research of South Florida, an AMR Company, Coral Gables

37920

AMR New Orleans, Formerly New Orleans Center for Clinical Research - New Orleans, an AMR company, Knoxville

64114

The Center for Pharmaceutical Research (CPR), Kansas City

67042

Heartland Research Associates, an AMR Company, El Dorado

68134

Meridian Clinical Research - Omaha, Omaha

68701

Meridian Clinical Research, LLC, Norfolk

73099

Tekton Research Inc., Yukon

92108

Optimal Research, San Diego

All Listed Sponsors
lead

Janssen Vaccines & Prevention B.V.

INDUSTRY

NCT04453202 - A Study to Evaluate a Range of Dose Levels of an Adenovirus Serotype 26 (Ad26.RSV.preF)-Based Vaccine in Older Adults | Biotech Hunter | Biotech Hunter